<DOC>
	<DOCNO>NCT00135031</DOCNO>
	<brief_summary>The purpose study determine dose-ranging efficacy safety profile encapsulate Bifidobacterium infantis 35624 female subject irritable bowel syndrome ( IBS ) .</brief_summary>
	<brief_title>Efficacy Encapsulated Probiotic Bifidobacterium Infantis 35624 Irritable Bowel Syndrome</brief_title>
	<detailed_description>The pathogenesis irritable bowel syndrome ( IBS ) may post-infectious inflammatory component , suggest alter gut bacterial flora relevance probiotic may beneficial . This clinical trial examine efficacy encapsulate probiotic subject Rome II IBS . After 2 week baseline , 362 female subject randomize placebo one three dos B. infantis 35624 daily 4 week . IBS symptom monitor daily score accord 6-point Likert scale ; stool frequency form also monitor daily . The primary efficacy variable abdominal pain score ; secondary efficacy variable include IBS symptom relief quality life .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Meet Rome II criterion diagnosis IBS Refrain use probiotic supplement trial Organic disease , include inflammatory bowel disease , significant systemic disease Subjects 55 year age sigmoidoscopy colonoscopy perform previous five year Use antipsychotic medication within prior three month Had major psychiatric disorder ( DSMIIR DSMIV ) , include major depression , psychosis , alcohol substance abuse , within past two year Were pregnant nursing Had know lactose intolerance immunodeficiency Had undergone abdominal surgery , exception hernia repair appendectomy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>